Renal dopaminergic mechanisms and hypertension: A chronology of advances

Clinical and Experimental Hypertension

Volumn 22, Issue 3, 2000, Pages 217-249

  O'Connell, Damian P ^a   Aherne, Anna M ^a  

^a NONE

Author keywords

Dopamine; Hypertension; Kidney

Indexed keywords

ADENYLATE CYCLASE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ELECTROLYTE; KALLIKREIN; KININ; PHOSPHOLIPASE A1; PHOSPHOLIPASE C; PROSTAGLANDIN; RENIN; WATER;

CONFERENCE PAPER; DIURESIS; DOPAMINERGIC SYSTEM; ELECTROLYTE EXCRETION; ELECTROLYTE TRANSPORT; ENZYME ACTIVITY; HORMONE RELEASE; HUMAN; HYPERTENSION; KALLIKREIN KININ SYSTEM; MOLECULAR DYNAMICS; NEUROENDOCRINOLOGY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY;

ANIMALS; BIOLOGICAL MARKERS; BLOOD PRESSURE; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; HUMANS; HYPERTENSION, RENAL; KALLIKREIN-KININ SYSTEM; KIDNEY; PROSTAGLANDINS; RECEPTORS, DOPAMINE; RENAL CIRCULATION;

EID: 0034105969     PISSN: 10641963     EISSN: None     Source Type: Journal    
DOI: 10.1081/CEH-100100074     Document Type: Conference Paper

References (231)

1. Euler USv, Lishajko F. Catecholamines in vascular wall. Acta. Physiol. Scand. 1958;42:333-341.
2. Goodall M. Studies of adrenaline and noradrenaline in mammalian hearts and suprarenals. Acta Physiologica Scandinavica 1951;24(Sup).
3. Berler A, Rosengren E. Occurrence and distribution of dopamine in brain and other tissues. Experientia 1959;15:10-11.
4. Euler USv, Lishajko F. Dopamine in mammalian lung and spleen. Acta. Physiol. Pharm. 1957;42:295-303.
5. Blaschko H. Metabolism and storage of biogenic amines. Experientia 1957;13: 9-12.
6. Neff NH, Hadjiconstantinou M, Lackovic Z. Dopamine: an endogenous peripheral neurotransmitter. In: Poste G, Crooke ST, editors. Dopamine Receptor Agonists, 1984.
7. Barger G, Dale HH. Chemical structure and sympathomimetic action of amines. Journal of Physiology, London 1910;41:19-59.
8. Hamet R. Contributiona l'etude de la dihydroxyphenylethyl amine. Arch. Int. Pharmacodyn. Ther. 1931;40:427-443.
9. Tainter ML. Comparative action of sympathomimetic compounds: The influence of cocaine and certain related compounds upon the action of a group of sympathomimetic amines. Quarterly Journal of Physiology 1930;3:584-598.
10. Holtz P, Credner K. Die enzymatische entstehung von oxytyramin im organismus und die physiologische bedeutung der dopadecarboxylase. Naunyn-Schmied. Arch. Pharmakol. Exp. Pathol 1942;200:356-388.
11. McDonald RHJ, Goldberg LI. Analysis of the cardiovascular effects of dopamine in the dog. J. Pharm. Exp. Ther. 1963;140:60-66.
12. Hornykiewicz O. The action of dopamine on the arterial blood pressure of the guinea pig. Brit. J. Pharm. 1958;13:91-94.
13. Goldberg LI, Sjoerdsma A. Effects of several monoamine oxidase inhibitors on the cardiovascular actions of naturally occurring amines in the dog. J. Pharmacol. Exp. Ther. 1959;127:212-218.
14. Holtz P, Stock K, Westermann E. Uber die blutdruck wirkung des dopamin. Naunyn-Schmied. Arch. Pharmakol. Exp. Pathol. 1963;246:133-146.
15. Holtz P, Stock K, Westermann E. Pharmacologie des tetrahydropapaverolins und seine entstehung aus dopamin. Naunyn-Schmied. Arch. Pharmakol. Exp. Pathol. 1964;248:387-405.
16. Halushka PV, Hoffmann PC. Does tetrahydroparaveroline contribute to the cardiovascular actions of dopamine? Biochem Pharmacol 1968;17(9):1873-80.
17. Goldberg LI. The pharmacological basis of the clinical use of dopamine. Proc R Soc Med 1977;70(Suppl 2):7-15.
18. Horwitz D, Fox SMG, L. I. Effects of dopamine in man. Circ. Res. 1962;10: 237-243.
19. Mc. Donald RHJ, Goldberg LI, McNay JL, Tuttle EP. Effects of dopamine in man: Augmentation of sodium excretion, glomerular filtration rate and renal plasma flow. J. Clin. Invest. 1964;43:1116-1124.
20. Goldberg LI, McDonald RHJ, Zimmerman AM. Sodium diuresis produced by dopamine in patients with congestive heart failure. N. Eng. J. Med. 1963;26: 1060-1064.
21. McNay JL, McDonald RHJ, Goldberg LI. Direct renal vasodilation produced by dopamine in the dog. Circ. Res. 1965;16:510-517.
22. Eble JN. A proposed mechanism for the depressor effect of dopamine in the anesthetized dog. J. Pharm. Exp. Ther. 1964;145:64-70.
23. Schuelke DM, Mark AL, Schmid PG, Eckstein JW. Coronary vasodilatation produced by dopamine after adrenergic blockade. J Pharmacol Exp Ther 1971; 176(2):320-7.
24. Yeh BK, McNay JL, Goldberg LI. Attenuation of dopamine renal and mesenteric vasodilation by haloperidol: evidence for a specific dopamine receptor. J Pharmacol Exp Ther 1969;168(2):303-9.
25. Day MD, Blower PR. Cardiovascular dopamine receptor stimulation antagonized by metoclopramide. J Pharm Pharmacol 1975;27(4):276-8.
26. Goldberg LI, Yeh BK. Attenuation of dopamine-induced renal vasodilation in the dog by phenothiazines. Eur J Pharmacol 1971;15(1):36-40.
27. Goldberg LI, Musgrave G. Attenuation of dopamine induced renal vasodilation by bulbocapnine and apomorphine. Pharmacologist 1971;13:227.
28. Kebabian JW, Greengard P. Dopamine-sensitive adenyl cyclase: possible role in synaptic transmission. Science 1971;174(16):1346-9.
29. Clement-Cormier YC, Kebabian JW, Petzold GL, Greengard P. Dopamine-sensitive adenylate cyclase in mammalian brain: a possible site of action of antipsychotic drugs. Proc Natl Acad Sci U S A 1974;71(4):1113-7.
30. Langer SZ. Presynaptic regulation of catecholamine release. Biochem Pharmacol 1974;23(13):1793-800.
31. Enero MA, Langer SZ. Inhibition by dopamine of 3H-noradrenaline release elicited by nerve stimulation in the isolated cat's nictitating membrane. Naunyn Schmiedebergs Arch Pharmacol 1975;289(2):179-203.
32. Long JP, Heintz S, Cannon JG, Kim J. Inhibition of the sympathetic nervous system by 5,6-dihydroxy-2- dimethylamino tetralin (M-7), apomorphine and dopamine. J Pharmacol Exp Ther 1975;192(2):336-42.
33. Bogaert MG, Schaepdryver AF, Willems JL. Dopamine-induced neurogenic vasodilatation in the intact hindleg of the dog. Br J Pharmacol 1977;59(2):283-92.
34. Willems JL, Bogaert MG. Ganglionic inhibition by dopamine and neurogenic vasodilatation, pp. 241-7. In: Vanhoutte PM, Leusen I, ed. Mechanisms of vasodilatation. Basel, Karger, 1978.
35. Willems JL, Buylaert WA, Bogaert MG. Evidence that dopamine receptors mediate the neurogenic vasodilation by dopaminergic agents. In: Imbs JL, Schwartz J, editors. Advances in the biosciences: peripheral dopaminergic receptors. New York: Pergamon Press, 1979:299-307.
36. Willems JL, Buylaert WA, Lefebvre RA, Bogaert MG. Neuronal dopamine receptors on autonomic ganglia and sympathetic nerves and dopamine receptors in the gastrointestinal system. Pharmacol Rev 1985;37(2):165-216.
37. Lokhandwala MF, Tadepalli AS, Jandhyala BS. Cardiovascular actions of bromocriptine: evidence for a neurogenic mechanism. J Pharmacol Exp Ther 1979; 211(3):620-5.
38. Kohli JD, Weder AB, Goldberg LI, Ginos JZ. Structure activity relationships of N-substituted dopamine derivatives as agonists of the dopamine vascular and other cardiovascular receptors. J Pharmacol Exp Ther 1980;213(2):370-4.
39. Buylaert WA, Willems JL, Bogaert MG. Vasodilatation produced by apomorphine in the hindleg of the dog. J Pharmacol Exp Ther 1977;201(3):738-46.
40. Goldberg LI, Volkman PH, Kohli JD. A comparison of the vascular dopamine receptor with other dopamine receptors. Annual Review of Pharmacology & Toxicology 1978;18:57-79.
41. Goldberg LI, Kohli JD. Peripheral dopamine receptors: a classification based on potency series and specific antagonism. Trends Pharmacol. Sci. 1983:64-66.
42. Shepperson NB, Duval N, Massingham R, Langer SZ. Differential blocking effects of several dopamine receptor antagonists for peripheral pre- and postsynaptic dopamine receptors in the anesthetized dog. J Pharmacol Exp Ther 1982;221(3): 753-61.
43. Goldberg LI, Kohli JD. Peripheral pre- and post-synaptic dopamine receptors: are they different from dopamine receptors in the central nervous system? Commun Psychopharmacol 1979;3(6):447-56.
44. Felder CC, McKelvey AM, Gitler MS, Eisner GM, Jose PA. Dopamine receptor subtypes in renal brush border and basolateral membranes. Kidney International 1989;36(2):183-93.
45. Mahan LC, Burch RM, Monsma FJ, Jr., Sibley DR. Expression of striatal D1 dopamine receptors coupled to inositol phosphate production and Ca2+ mobilization in Xenopus oocytes. Proc Natl Acad Sci U S A 1990;87(6):2196-200.
46. Hussain T, Lokhandwala MF. Renal dopamine DA1 receptor coupling with G(S) and G(q/11) proteins in spontaneously hypertensive rats. Am J Physiol 1997;272(3 Pt 2):F339-46.
47. Memo M, Castelletti L, Missale C, Spano P. Stimulation of dopamine d-2 receptors increases potassium permeability in mamotrophs. Eur J Pharmacol 1987;139: 361-362.
48. Sibley DR, Monsma FJ, Jr., McVittie LD, Gerfen CR, Burch RM, Mahan LC. Molecular neurobiology of dopamine receptor subtypes. Neurochemistry International 1992;20 Suppl:17S-22S.
49. Liu LX, Monsma FJ, Jr., Sibley DR, Chiodo LA. D2L, D2S, and D3 dopamine receptors stably transfected into NG108-15 cells couple to a voltage-dependent potassium current via distinct G protein mechanisms. Synapse 1996;24(2):156-64.
50. Watts VJ, Neve KA. Activation of type II adenylate cyclase by D2 and D4 but not D3 dopamine receptors. Molecular Pharmacology 1997;52(2):181-6.
51. Wilke RA, Hsu SF, Jackson MB. Dopamine D4 receptor mediated inhibition of potassium current in neurohypophysial nerve terminals. J Pharmacol Exp Ther 1998;284(2):542-8.
52. Malgaroli A, Vallar L, Elahi FR, Pozzan T, Spada A, Meldolesi J. Dopamine inhibits cytosolic Ca2+ increases in rat lactotroph cells. Evidence of a dual mechanism of action. J Biol Chem 1987;262(29):13920-7.
53. Vallar L, Meldolesi J. Mechanisms of signal transduction at the dopamine D2 receptor. Trends Pharmacol Sci 1989;10(2):74-7.
54. Lledo PM, Homburger V, Bockaert J, Vincent JD. Differential G protein-mediated coupling of D2 dopamine receptors to K+ and Ca2+ currents in rat anterior pituitary cells. Neuron 1992;8(3):455-63.
55. Osipenko ON, Varnai P, Mike A, Spat A, Vizi ES. Dopamine blocks T-type calcium channels in cultured rat adrenal glomerulosa cells. Endocrinology 1994;134(1): 511-4.
56. Formenti A, Martina M, Plebani A, Mancia M. Multiple modulatory effects of dopamine on calcium channel kinetics in adult rat sensory neurons. J Physiol (Lond) 1998;509(Pt 2):395-409.
57. Vallar L, Vicentini LM, Meldolesi J. Inhibition of inositol phosphate production is a late, Ca2+-dependent effect of D2 dopaminergic receptor activation in rat lactotroph cells. J Biol Chem 1988;263(21):10127-34.
58. Kimura K, Sela S, Bouvier C, Grandy DK, Sidhu A. Differential coupling of D1 and D5 dopamine receptors to guanine nucleotide binding proteins in transfected GH4C1 rat somatomammotrophic cells. J Neurochem 1995;64(5):2118-24.
59. Pizzi M, Da Prada M, Valerio A, Memo M, Spano PF, Haefely WE. Dopamine D2 receptor stimulation inhibits inositol phosphate generating system in rat striatal slices. Brain Res 1988;456(2):235-40.
60. Undie AS, Friedman E. Inhibition of dopamine agonist-induced phosphoinositide hydrolysis by concomitant stimulation of cyclic AMP formation in brain slices. J Neurochem 1994;63(1):222-30.
61. Kanterman RY, Mahan LC, Briley EM, Monsma FJ, Jr., Sibley DR, Axelrod J, Felder CC. Transfected D2 dopamine receptors mediate the potentiation of arachidonic acid release in Chinese hamster ovary cells. Molecular Pharmacology 1991; 39(3):364-9.
62. Zahniser NR, Cass WA, Fitzpatrick FA. Signal transduction pathways involved in presynaptic receptor-mediated inhibition of dopamine release in rat striatum. Neurochem Int 1992;20 Suppl:85S-88S.
63. McAllister G, Knowles MR, Patel S, Marwood R, Emms F, Seabrook GR, Graziano M, Borkowski D, Hey PJ, Freedman SB. Characterisation of a chimeric hD3/D2 dopamine receptor expressed in CHO cells. FEBS Lett 1993;324(1):81-6.
64. Schinelli S, Paolillo M, Corona GL. Opposing actions of D1-and D2-dopamine receptors on arachidonic acid release and cyclic AMP production in striatal neurons. J Neurochem 1994;62(3):944-9.
65. Nilsson CL, Hellstrand M, Ekman A, Eriksson E. Direct dopamine D2-receptor-mediated modulation of arachidonic acid release in transfected CHO cells without the concomitant administration of a Ca2+-mobilizing agent. Br J Pharmacol 1998; 124(8):1651-8.
66. Meister B, Fryckstedt J, Schalling M, Cortes R, Hokfelt T, Aperia A, Hemmings HC, Jr., Nairn AC, Ehrlich M, Greengard P. Dopamine-and cAMP-regulated phosphoprotein (DARPP-32) and dopamine DA1 agonist-sensitive Na+,K+-ATPase in renal tubule cells. Proc Natl Acad Sci U S A 1989;86(20):8068-72.
67. Aperia A, Fryckstedt J, Svensson L, Hemmings HC, Jr., Nairn AC, Greengard P. Phosphorylated Mr 32,000 dopamine-and cAMP-regulated phosphoprotein inhibits Na+,K(+)-ATPase activity in renal tubule cells. Proceedings of the National Academy of Sciences of the United States of America 1991;88(7):2798-801.
68. Li D, Aperia A, Celsi G, da Cruz e Silva EF, Greengard P, Meister B. Protein phosphatase-1 in the kidney: evidence for a role in the regulation of medullary Na(+)-K(+)-ATPase. American Journal of Physiology 1995;269(5 Pt 2):F673-80.
69. Nishi A, Snyder GL, Greengard P. Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J Neurosci 1997;17(21):8147-55.
70. Brene S, Hall H, Lindefors N, Karlsson P, Halldin C, Sedvall G. Distribution of messenger RNAs for D1 dopamine receptors and DARPP-32 in striatum and cerebral cortex of the cynomolgus monkey: relationship to D1 dopamine receptors. Neuroscience 1995;67(1):37-48.
71. Slobodyansky E, Aoki Y, Gaznabi AK, Aviles DH, Fildes RD, Jose PA. Dopamine and protein phosphatase activity in renal proximal tubules. Am J Physiol 1995;268(2 Pt 2):F279-84.
72. Dearry A, Gingrich JA, Falardeau P, Fremeau RT, Jr., Bates MD, Caron MG. Molecular cloning and expression of the gene for a human D1 dopamine receptor. Nature 1990;347(6288):72-76.
73. Zhou QY, Grandy DK, Thambi L, Kushner JA, Van Tol HHM, Cone R, Pribnow D, Salon J, Bunzow JR, Civelli O.. Cloning and expression of human and rat D1 dopamine receptors. Nature 1990;347(6288):76-80.
74. Monsma FJ, Jr., Mahan LC, McVittie LD, Gerfen CR, Sibley DR. Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation. Proceedings of the National Academy of Sciences of the United States of America 1990;87(17):6723-7.
75. Sunahara RK, Niznik HB, Weiners DM, Stormann TM, Brann MR, Kennedy JL, Gelernter JE, Rozmahel R, Yang Y, Israel Y, Seeman P, O'Dowd BF. Human dopamine D1 receptor encoded by an intronless gene on chromosome 5. Nature 1990;347(6288):80-83.
76. Sunahara R, Guan H, O'Dowd B, Seeman P, Laurier L, Ng G. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 1991;350:614-19.
77. Grandy DK, Zhang YA, Bouvier C, Zhou QY, Johnson RA, Allen L, Buck K, Bunzow JR, Salon J, Civelli O. Multiple human D5 dopamine receptor genes: a functional receptor and two pseudogenes. Proc Natl Acad Sci U S A 1991;88(20): 9175-9.
78. Tiberi M, Jarvie KR, Silvia C, Falardeau P, Gingrich JA, Godinot N, Betrand L, Yang-Feng TL, Fremeau RT, Jr., Caron MG. Cloning, molecular characterization, and chromosomal assignment of a gene encoding a second D1 dopamine receptor subtype: differential expression pattern in rat brain compared with the D1A receptor. Proc Natl Acad Sci U S A 1991;88(17):7491-5.
79. Weinshank RL, Adham N, Macchi M, Olsen MA, Branchek TA, Hartig PR. Molecular cloning and characterization of a high affinity dopamine receptor (D1 beta) and its pseudogene. J Biol Chem 1991;266(33):22427-35.
80. Bunzow JR, Van Tol HH, Grandy DK, Albert P, Salon J, Christie M, Machida CA, Neve KA, Civelli O. Cloning and expression of a rat D2 dopamine receptor cDNA [see comments]. Nature 1988;336(6201):783-7.
81. Dal Toso R, Sommer B, Ewert M, Herb A, Pritchett DB, Bach A, Shivers BD, Seeburg PH. The dopamine D2 receptor: two molecular forms generated by alternative splicing. Embo J 1989;8(13):4025-34.
82. Monsma FJ, Jr., McVittie LD, Gerfen CR, Mahan LC, Sibley DR. Multiple D2 dopamine receptors produced by alternative RNA splicing. Nature 1989;342(6252):926-9.
83. Chio CL, Hess GF, Graham RS, Huff RM. A second molecular form of D2 dopamine receptor in rat and bovine caudate nucleus. Nature 1990;343(6255): 266-9.
84. Giros B, Martres MP, Sokoloff P, Schwartz JC. [Gene cloning of human dopaminergic D3 receptor and identification of its chromosome]. C R Acad Sci III 1990;311(13):501-8.
85. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990;347(6289):146-51.
86. Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350(6319):610-4.
87. Civelli O, Bunzow JR, Grandy DK, Zhou QY, Van Tol HHM. Molecular biology of the dopamine receptors. Eur. J. Pharmacol. Mol. Pharmacol. 1991;207(4):277-286.
88. Civelli O, Bunzow JR, Grandy DK. Molecular diversity of the dopamine receptors. Annu Rev Pharmacol Toxicol 1993;33:281-307.
89. Kulkarni SK, Ninan I. Current concepts in the molecular diversity and pharmacology of dopamine receptors. Methods Find Exp Clin Pharmacol 1996;18(9): 599-613.
90. Lachowicz JE, Sibley DR. Molecular characteristics of mammalian dopamine receptors. Pharmacology & Toxicology 1997;81(3):105-13.
91. Hartman DS, Lanau F. Diversity of dopamine receptors: new molecular and pharmacological developments. Pol J Pharmacol 1997;49(4):191-9.
92. Holtz P, Credner K, Koepp W. Die enzymatische entstehung von oxytyramin im organismus und die physiologische bedeutung der dopadecarboxylase. Naunyn. Schmied. Arch. Pharmacol. Exp. Pathol 1942:356-388.
93. Crout JR. Sampling and analysis of catecholamines and metabolites. Anesthesiology 1968;29(4):661-9.
94. Barthelmebs M, Vailly B, Velly J, Ehrhardt JD, Grima M, Imbs JL. Renal dopamine synthesis from precursors. Am J Hypertens 1990;3(6 Pt 2):18S-21S.
95. Soares da Silva P, Fernandes MH. A Study On the Renal Synthesis Of Dopamine In Aged Rats. Acta Physiologica Scandinavica 1991;143(3):287-293.
96. Soares-da-Silva P, Fernandes MH, Pinto-do OP. Cell inward transport of L-DOPA and 3-O-methyl-L-DOPA in rat renal tubules. Br J Pharmacol 1994;112(2):611-5.
97. Goldstein M, Fuxe K, Hokfelt T. Characterization and tissue localization of catecholamine synthesizing enzymes. Pharmacol Rev 1972;24(2):293-309.
98. Hayashi M, Yamaji Y, Kitajima W, Saruta T. Aromatic L-amino acid decarboxylase activity along the rat nephron. Am J Physiol 1990;258(1 Pt 2):F28-33.
99. Ball SG, Lee MR. The effect of carbidopa administration on urinary sodium excretion in man. Is dopamine an intrarenal natriuretic hormone? Br J Clin Pharmacol 1977;4(2):115-9.
100. Baines AD, Chan W. Production of urine free dopamine from DOPA; a micropuncture study. Life Sci 1980;26(4):253-9.
101. Brown MJ, Allison DJ. Renal conversion of plasma DOPA to urine dopamine [letter]. Br J Clin Pharmacol 1981;12(2):251-3.
102. Lee MR. Dopamine and the kidney. Clin Sci 1982;62(5):439-48.
103. Dinerstein RJ, Vannice J, Henderson RC, Roth LJ, Goldberg LI, Hoffmann PC. Histofluorescence techniques provide evidence for dopamine-containing neuronal elements in canine kidney. Science 1979;205(4405):497-9.
104. Huo T, Healy DP. Autoradiographic localization of dopamine DA1 receptors in rat kidney with (3H)Sch 23390. Am. J. Physiol., Renal Fluid Electrolyte Physiol 1989; 257(3):F414-F423.
105. Amenta F. Density and distribution of dopamine receptors in the cardiovascular system and in the kidney. Journal of Autonomic Pharmacology 1990;10 Suppl 1:s11-8.
106. Felder RA, Jose PA. Dopamine 1 receptors in rat kidneys identified with 125I-Sch 23982. Am. J. Physiol., Renal Fluid Electrolyte Physiol 1988;255(5):F970-6.
107. Felder RA, Felder CC, Eisner GM, Jose PA. The dopamine receptor in adult and maturing kidney. Am. J. Physiol., Renal Fluid Electrolyte Physiol 1989;257(3): F315-27.
108. Felder RA, Blecher M, Eisner GM, Jose PA. Cortical tubular and glomerular dopamine receptors in the rat kidney. American Journal of Physiology 1984;246(5 Pt 2):F557-68.
109. Takemoto F, Satoh T, Cohen HT, Katz AI. Localization of dopamine-1 receptors along the microdissected rat nephron. Pflugers Arch 1991;419(3-4):243-8.
110. Ohbu K, Felder RA. DA1 dopamine receptors in renal cortical collecting duct. Am J Physiol 1991;261(5 Pt 2):F890-5.
111. Altar CA, Marien MR. Picomolar affinity of 125I-SCH 23982 for D1 receptors in brain demonstrated with digital subtraction autoradiography. J Neurosci 1987; 7(1):213-22.
112. Lokhandwala MF, Amenta F. Anatomical distribution and function of dopamine receptors in the kidney. Faseb J 1991;5(15):3023-3030.
113. Amenta F. Density and Distribution Of Dopamine-Receptors In the Cardiovascular-System and In the Kidney. Journal Of Autonomic Pharmacology 1990;10:S11-S18.
114. Ricci A, Rossodivita A, Amenta F. Dopamine DA-2 receptor sites in the rat renal cortex: A light microscope autoradiographic study. Naunyn Schmiedeberg'S Arch. Pharmacol. 1991;344(2):259-261.
115. Huo T, Ye MQ, Healy DP. Characterization Of a Dopamine Receptor (Da2k) In the Kidney Inner Medulla. Proceedings Of The National Academy Of Sciences Of The United States Of America 1991;88(8):3170-3174.
116. Missale C, Castelletti L, Memo M, Carruba MO, Spano PF. Identification and characterization of postsynaptic D1- and D2-dopamine receptors in the cardiovascular system. J Cardiovasc Pharmacol 1988;11(6):643-50.
117. Ricci A, Collier WL, Rossodivita I, Amenta F. Dopamine receptors mediating inhibition of the cyclic adenosine monophosphate generating system in the rat renal cortex. Journal of Autonomic Pharmacology 1991;11(2):121-7.
118. O'Connell DP, Botkin SJ, Ramos SI, Sibley DR, Ariano MA, Felder RA, Carey RM. Localization of dopamine D1A receptor protein in rat kidneys. Am J Physiol 1995;268(6 Pt 2):F1185-97.
119. O'Connell DP. Expression of newly cloned brain dopamine receptors in peripheral organs. Biochem Soc Trans 1996;24(1):169-72.
120. Ozono R, O'Connell DP, Wang ZQ, Moore AF, Sanada H, Felder RA, Carey RM. Localization of the dopamine D1 receptor protein in the human heart and kidney. Hypertension 1997;30(3 Pt 2):725-9.
121. O'Connell DP, Vaughan CJ, Aherne AM, Botkin SJ, Wang ZQ, Felder RA, Carey RM. Expression of the dopamine D3 receptor protein in the rat kidney. Hypertension 1998;32(5):886-95.
122. Sun D, Wilborn TW, Schafer JA. Dopamine D4 receptor isoform mRNA and protein are expressed in the rat cortical collecting duct. Am J Physiol 1998;275(5 Pt 2):F742-51.
123. Amenta F, Barili P, Bronzetti E, Ricci A. Dopamine D1-like receptor subtypes in the rat kidney: a microanatomical study. Clin Exp Hypertens 1999;21(1-2):17-23.
124. Yamaguchi I, Jose PA, Mouradian MM, Canessa LM, Monsma FJ, Jr., Sibley DR, Takeyasu K, Felder RA. Expression of dopamine D1A receptor gene in proximal tubule of rat kidneys. American Journal of Physiology 1993;264(2 Pt 2):F280-5.
125. Gao DQ, Canessa LM, Mouradian MM, Jose PA. Expression of the D2 subfamily of dopamine receptor genes in kidney. Am J Physiol 1994;266(4 Pt 2):F646-50.
126. O'Connell DP, Aherne AM, Lane E, Felder RA, Carey RM. Detection of dopamine receptor D1A subtype-specific mRNA in rat kidney by in situ amplification. Am J Physiol 1998;274(1 Pt 2):F232-41.
127. Yao LP, Jose PA. Developmental renal hemodynamics. Pediatr Nephrol 1995; 9(5):632-7.
128. Sanada H, Yao L, Jose PA, Carey RM, Felder RA. Dopamine D3 receptors in rat juxtaglomerular cells. Clin Exp Hypertens 1997;19(1-2):93-105.
129. Jose PA, Raymond JR, Aperia A, Felder RA, Carey RM. The Renal Dopamine-Receptors. Journal Of The American Society Of Nephrology 1992;2(8):1265-1278.
130. Goldberg LI, Kohli JD, Glock D. Conclusive evidence for two subtypes of peripheral dopamine receptors. In: Woodruff G, Poat J, Roberts P, editors. Dopaminergic Systems and their Regulation. London: MacMillan Press, 1986:195-212.
131. Felder RA, Carey RM. Dopamine in cardiovascular function. In: Buckley N, Ferrario C, editors. Brain Peptides and Catecholamines in Cardiovascular Regulation in Normal and Disease States. New York: Raven Press, 1987:79-91.
132. Kambara S, Yoneda S, Yoshimura M, Yamazaki H, Okabayashi H, Takeda K, Takahashi H, Ijichi H. [The source and significance of increased urinary dopamine excretion during sodium loading in rats]. Nippon Naibunpi Gakkai Zasshi 1987; 63(5):657-63.
133. Wang ZQ, Siragy HM, Felder RA, Carey RM. Intrarenal dopamine production and distribution in the rat. Physiological control of sodium excretion. Hypertension 1997;29(1 Pt 2):228-34.
134. Eklof AC, Holtback U, Sundelof M, Chen S, Aperia A. Inhibition of COMT induces dopamine-dependent natriuresis and inhibition of proximal tubular Na+,K+-ATPase. Kidney International 1997;52(3):742-7.
135. Siragy HM, Felder RA, Howell NL, Chevalier RL, Peach MJ, Carey RM. Evidence that intrarenal dopamine acts as a paracrine substance at the renal tubule. Am. J. Physiol. 1989;257(3, Pt. 2):F469-F477.
136. Carey RM, Siragy HM, Felder RA. Physiological modulation of renal function by the renal dopaminergic system. J. Auton. Pharmacol. 1990;1:s47-s51.
137. Vyas SJ, Apparsundaram S, Ricci A, Amenta F, Lokhandwala MF. Biochemical, Autoradiographic and Pharmacological Evidence For the Involvement Of Tubular Da-1 Receptors In the Natriuretic Response to Dopexamine Hydrochloride. Naunyn Schmiedebergs Archives Of Pharmacology 1991;343(1):21-30.
138. Allison NL, Dubb JW, Ziemniak JA, Alexander F, Stote RM. The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamics. Clin Pharmacol Ther 1987;41(3):282-8.
139. Hegde SS, Lokhandwala MF. Renal dopamine and sodium excretion. Am J Hypertens 1990;3(6 Pt 2):78S-81S.
140. Hegde SS, Rocci A, Amenta F, Lokhandwala MF. Evidence from functional and autoradiographic studies for the presence of tubular dopamine-1 receptors and their involvement in the renal effects of fenoldopam. J. Pharmacol. Exp. Ther. 1989; 251(3):1237-1245.
141. Hughes JM, Beck TR, Rose CE, Jr., Carey RM. Selective dopamine-1 receptor stimulation produces natriuresis by a direct tubular action. J Hypertens Suppl 1986; 4(6):S106-8.
142. Siragy HM, Felder RA, Howell NE, Chevalier RL, Peach MJ, Carey RM. Intrarenal dopamine acts at the dopamine-1 receptor to control renal function. Journal of Hypertension - Supplement 1988;6(4):S479-81.
143. Hughes JM, Ragsdale NV, Felder RA, Chevalier RL, King B, Carey RM. Diuresis and natriuresis during continuous dopamine-1 receptor stimulation. Hypertension 1988;11(2 Pt 2):I69-74.
144. Lokhandwala MF, Vyas SJ, Hegde SS. Renal dopamine and tubular DA-1 receptors in the regulation of sodium excretion. J Auton Pharmacol 1990;10 Suppl 1:s31-9.
145. Chen C, Lokhandwala MF. Inhibition of sodium-potassium-ATPase in rat renal proximal tubules by dopamine involved DA-1 receptor activation. Naunyn-Schmiedeberg's Arch. Pharmacol. 1993;347(3):289-95.
146. Macdonald TM. Metoclopramide, Domperidone and Dopamine In Man - Actions and Interactions. European Journal Of Clinical Pharmacology 1991;40(3): 225-230.
147. Wang ZQ, Felder RA, Carey RM. Selective inhibition of the renal dopamine subtype D1A receptor induces antinatriuresis in conscious rats. Hypertension 1999; 33(1 Pt 2):504-10.
148. Aperia AC. Dopamine inhibition of NaKATPase activity in proximal convoluted tubule cells. Progress in Clinical & Biological Research 1988;273:427-34.
149. Grider J, Kilpatrick E, Ott C, Jackson B. Effect of dopamine on NaCl transport in the medullary thick ascending limb of the rat. European Journal of Pharmacology 1998;342:281-4.
150. Takemoto F, Cohen HT, Satoh T, Katz AI. Dopamine inhibits Na/K-ATPase in single tubules and cultured cells from distal nephron. Pflugers Arch 1992;421(4): 302-6.
151. Chen CJ, Vyas SJ, Eichberg J, Lokhandwala MF. Diminished phospholipase C activation by dopamine in spontaneously hypertensive rats. Hypertension 1992; 19(1): 102-8.
152. Felder CC, Campbell T, Albrecht F, Jose PA. Dopamine inhibits Na(+)-H+ exchanger activity in renal BBMV by stimulation of adenylate cyclase. Am J Physiol 1990;259(2 Pt 2):F297-303.
153. Dawirs RR, Teuchert-Noodt G. Demonstration of dopamine-immunoreactive cells in the proximal convoluted tubule of gerbil (Meriones unguiculatus) kidney. J Histochem Cytochem 1992;40(11):1685-91.
154. Bertorello A, Hokfelt T, Goldstein M, Aperia A. Proximal tubule Na+-K+-ATPase activity is inhibited during high-salt diet: evidence for DA-mediated effect. American Journal of Physiology 1988;254(6 Pt 2):F795-801.
155. Aperia A, Bertorello A, Seri I. Dopamine causes inhibition of Na+-K+-ATPase activity in rat proximal convoluted tubule segments. Am J Physiol 1987;252(1 Pt 2):F39-45.
156. Eklof AC. The natriuretic response to adopamine DA1 agonist requires endogenous activation of dopamine DA2 receptors. Acta Physiol Scand 1997;160(4):311-4.
157. Jose PA, Asico LD, Eisner GM, Pocchiari F, Semeraro C, Felder RA. Effects of costimulation of dopamine D1- and D2-like receptors on renal function. Am J Physiol 1998;275(4 Pt 2):R986-94.
158. Muto S, Tabei K, Asano Y, Imai M. Dopaminergic inhibition of the action of vasopressin on the cortical collecting tubule. European Journal of Pharmacology 1985;114:393-7.
159. Chen C, Lokhandwala MF. Potentiation by enalaprilat of fenoldopam-evoked natriuresis is due to blockade of intrarenal production of angiotensin-II in rats. Naunyn Schmiedebergs Arch Pharmacol 1995;352(2):194-200.
160. Sun D, Schafer JA. Dopamine inhibits AVP-dependent Na+ transport and water permeability in rat CCD via a D4-like receptor. Am J Physiol 1996;271(2 Pt 2):F391-400.
161. Li L, Schafer JA. Dopamine inhibits vasopressin-dependent cAMP production in the rat cortical collecting duct. Am J Physiol 1998;275(1 Pt 2):F62-7.
162. Steinhausen M, Weis S, Fleming J, Dussel R, Parekh N. Responses of in vivo renal microvessels to dopamine. Kidney Int 1986;30(3):361-70.
163. Schmidt M, Imbs JL, Giesen EM, Schwartz J. Vasodilator effects of dopaminomimetics in the perfused rat kidney. Eur J Pharmacol 1982;84(1-2): 61-70.
164. Schmidt M, Imbs JL. Pharmacological characterization of renal vascular dopamine receptors. J Cardiovasc Pharmacol 1980;2(5):595-605.
165. Kinter LB, Horner E, Mann WA, Weinstock J, Ruffolo RR, Jr. Characterization of the hemodynamic activities of fenoldopam and its enantiomers in the dog. Chirality 1990;2(4):219-25.
166. Smit AJ, Meijer S, Wesseling H, Reitsma WD, Donker AJ. Impaired renal hemodynamic but conserved natriuretic response to dopamine in patients with renal disease. Nephron 1989;52(4):338-46.
167. Setler PE, Sarau HM, Zirkle CL, Saunders HL. The central effects of a novel dopamine agonist. Eur J Pharmacol 1978;50(4):419-30.
168. Baldi E, Pupilli C, Amenta F, Mannelli M. Presence of dopamine-dependent adenylate cyclase activity in human renal cortex. Eur. J. Pharmacol. 1988;149(3):351-6.
169. Lokhandwala MF, Jandhyala BS. The role of sympathetic nervous system in the vascular actions of dopamine. J Pharmacol Exp Ther 1979;210(1):120-6.
170. Henry DP, Aoi W, Weinberger MH. The effects of dopamine on renin release in vitro. Endocrinology 1977;101(1):279-83.
171. Quesada T, Garcia-Torres L, Alba F, Garcia del Rio C. The effects of dopamine on renin release in the isolated perfused rat kidney. Experientia 1979;35(9):1205.
172. Imbs JL, Schmidt M, Schwartz J. Effect of dopamine on renin secretion in the anesthetized dog. Eur J Pharmacol 1975;33(1):151-7.
173. Kurtz A, Della Bruna R, Pratz J, Cavero I. Rat juxtaglomerular cells are endowed with DA-1 dopamine receptors mediating renin release. J Cardiovasc Pharmacol 1988;12(6):658-63.
174. Antonipillai I, Broers MI, Lang D. Evidence that specific dopamine-1 receptor activation is involved in dopamine-induced renin release. Hypertension 1989;13(5): 463-8.
175. Chen CJ, Apparsundaram S, Lokhandwala MF. Intrarenally produced angiotensin II opposes the natriuretic action of the dopamine-1 receptor agonist fenoldopam in rats. J Pharmacol Exp Ther 1991;256(2):486-91.
176. Carey RM, Geary KM, Hunt MK, Ramos SP, Forbes MS, Inagami T, Peach MJ, Leong DA. Identification of individual renocortical cells that secrete renin. Am J Physiol 1990;258(3 Pt 2):F649-59.
177. Hunt MK, Ramos SP, Geary KM, Norling LL, Peach MJ, Gomez RA, Carey RM. Colocalization and release of angiotensin and renin in renal cortical cells. Am J Physiol 1992;263(3 Pt 2):F363-73.
178. Murphy MB, McCoy CE, Weber RR, Frederickson ED, Douglas FL, Goldberg LI. Augmentation of renal blood flow and sodium excretion in hypertensive patients during blood pressure reduction by intravenous administration of the dopamine 1 agonist fenoldopam. Circulation 1987;76(6):1312-8.
179. Hughes JM, Beck TR, Rose CE, Jr., Carey RM. The effect of selective dopamine-1 receptor stimulation on renal and adrenal function in man. J Clin Endocrinol Metab 1988;66(3):518-25.
180. Harvey JN, Worth DP, Brown J, Lee MR. The effect of oral fenoldopam (SKF 82526-J), a peripheral dopamine receptor agonist, on blood pressure and renal function in normal man. Br J Clin Pharmacol 1985;19(1):21-7.
181. Harvey JN, Worth DP, Brown J, Lee MR. Studies with fenoldopam, a dopamine receptor DA1 agonist, in essential hypertension. Br J Clin Pharmacol 1986; 21(1):53-61.
182. Williams BC, Eglen A, Duncan FM, Edwards CR. The effect of sodium intake on the renin response to dopamine in superfused rat renal cortical cells. J Hypertens Suppl 1985;3 Suppl 3:S267-8.
183. Francis GS, Wilson BC, Rector TS. Hemodynamic, renal, and neurohumoral effects of a selective oral DA1 receptor agonist (fenoldopam) in patients with congestive heart failure. Am Heart J 1988;116(2 Pt 1):473-9.
184. Worth DP, Harvey JN, Brown J, Worral A, Lee MR. Domperidone treatment in man inhibits the fall in plasma renin activity induced by intravenous gamma-L-glutamyl-L-dopa. Br J Clin Pharmacol 1986;21(5):497-502.
185. Asico LD, Ladines C, Fuchs S, Accili D, Carey RM, Semeraro C, Pocchiaria F, Felder RA, Eisner GM, Jose PA. Disruption of the dopamine D3 receptor gene produces renin-dependent hypertension. J Clin Invest 1998;102(3):493-8.
186. Kuchel O, Buu NT, Hamet P, Larochelle P, Bourque M, Genest J. Dopamine surges in hyperadrenergic essential hypertension. Hypertension 1982;4(6):845-52.
187. Guyton AC, Granger HJ, Coleman TG. Autoregulation of the total systemic circulation and its relation to control of cardiac output and arterial pressure. Circ Res 1971;28:Suppl 1:93-7.
188. Fink GD, Takeshita A, Mark AL, Brody MJ. Determinants of renal vascular resistance in the Dahl strain of genetically hypertensive rat. Hypertension 1980;2(3): 274-80.
189. Wyss JM, Liumsiricharoen M, Sripairojthikoon W, Brown D, Gist R, Oparil S. Exacerbation of hypertension by high chloride, moderate sodium diet in the salt-sensitive spontaneously hypertensive rat. Hypertension 1987;9(6 Pt 2):III171-5.
190. Nishi A, Eklof AC, Bertorello AM, Aperia A. Dopamine regulation of renal Na+,K(+)-ATPase activity is lacking in Dahl salt-sensitive rats. Hypertension 1993;21(6 Pt 1):767-71.
191. DeFeo ML, Jadhav AL, Lokhandwala MF. Dietary sodium intake and urinary dopamine and sodium excretion during the course of blood pressure development in Dahl salt-sensitive and salt-resistant rats. Clin Exp Hypertens [A] 1987;9(12): 2049-60.
192. Racz K, Kuchel O, Buu NT. Abnormal adrenal catecholamine synthesis in salt-sensitive Dahl rats. Hypertension 1987;9(1):76-80.
193. Yoshimura M, Kambara S, Okabayashi H, Takahashi H, Ijichi H. Effect of decreased dopamine synthesis on the development of hypertension induced by salt loading in spontaneously hypertensive rats. Clin Exp Hypertens [A] 1987;9(7): 1141-57.
194. Kinoshita S, Sidhu A, Felder RA. Defective dopamine-1 receptor adenylate cyclase coupling in the proximal convoluted tubule from the spontaneously hypertensive rat. J Clin Invest 1989;84(6):1849-56.
195. Chen C, Beach RE, Lokhandwala MF. Dopamine fails to inhibit renal tubular sodium pump in hypertensive rats. Hypertension 1993;21(3):364-72.
196. Ohbu K, Kaskel FJ, Kinoshita S, Felder RA. Dopamine-1 receptors in the proximal convoluted tubule of Dahl rats: defective coupling to adenylate cyclase. Am J Physiol 1995;268(1 Pt 2):R231-5.
197. Asico LD, Eisner GM, Jose PA. Renal nerves and D-1-dopamine receptor-mediated natriuresis. Clinical and Experimental Hypertension 1998;20(2):259-271.
198. Vachvanichsanong P, Kimura K, Sidhu A. Differences in photoaffinity labeling of DA1 receptors in renal proximal tubules from normotensive rat and SHR. Am J Physiol 1995;268(6 Pt 2):F1009-16.
199. Ohbu K, Felder RA. Nephron specificity of dopamine receptor-adenylyl cyclase defect in spontaneous hypertension. Am J Physiol 1993;264(2 Pt 2):F274-9.
200. Felder RA, Kinoshita S, Ohbu K, Mouradian MM, Sibley DR, Monsma FJ, Jr., Minowa T, Minowa MT, Canessa LM, Jose PA. Organ specificity of the dopamine 1 receptor/adenylyl cyclase coupling defect in spontaneously hypertensive rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 1993;264(4):R726-32.
201. Kansra V, Chen CJ, Lokhandwala MF. Dopamine fails to stimulate protein kinase C activity in renal proximal tubules of spontaneously hypertensive rats. Clin Exp Hypertens 1995;17(5):837-45.
202. Lokhandwala MF, Kansra V, Chen C. Dopaminergic modulation of Na,K-ATPase activity in the proximal tubules of normotensive and hypertensive rats. Hypertens Res 1995;18Suppl 1:843-6.
203. Jose PA, Eisner GM, Drago J, Carey RM, Felder RA. Dopamine receptor signaling defects in spontaneous hypertension. Am J Hypertens 1996;9(4 Pt 1):400-5.
204. Yao LP, Li XX, Yu PY, Xu J, Asico LD, Jose PA. Dopamine D1 receptor and protein kinase C isoforms in spontaneously hypertensive rats. Hypertension 1998; 32(6):1049-53.
205. Vachvanichsanong P, Sela S, Sidhu A. Absence of DA1/DA2 dopamine receptor interactions in proximal tubules of spontaneously hypertensive rats. Am J Physiol 1996;270(1 Pt 2):F98-105.
206. Albrecht FE, Drago J, Felder RA, Printz MP, Eisner GM, Robillard JE, Sibley DR, Westphal HJ, Jose PA. Role of the D1A dopamine receptor in the pathogenesis of genetic hypertension. Journal of Clinical Investigation 1996;97(10):2283-8.
207. Hussain T, Abdul-Wahab R, Kotak DK, Lokhandwala MF. Bromocriptine regulates angiotensin II response on sodium pump in proximal tubules. Hypertension 1998; 32(6):1054-1059.
208. Barbeau A. Dopamine and disease. Can Med Assoc J 1970;103(8):824-32.
209. Goldberg LI. Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacol Rev 1972;24(1):1-29.
210. Serrano P, Figueroa G, Torres M, Del Angel AR. Adrenaline, noradrenaline and dopamine excretion in patients with essential hypertension. American Journal of Cardiology 1964;13:484-88.
211. Januszewicz W, Wocial B, Kaliszuk T. Urinary dopamine excretion in patients with hypertension. Pol Med J 1968;7(1):26-31.
212. Iimura O, Shimamoto K, Ura N, Nakagawa M, Nishimiya T, Ando T, Yamaguchi Y, Masuda A, Ogata H, Saito S. The pathophysiological role of renal dopamine, kallikrein kinin and prostaglandin systems in essential hypertension. Agents Actions Suppl 1987;22:247-56.
213. Aoki K, Kikuchi K, Yamaji I, Nishimura M, Honma C, Kobayakawa H, Yamamoto M, Kudoh C, Shimazaki M, Sakamoto T. Attenuated renal production of dopamine in patients with low renin essential hypertension. Clin Exp Hypertens [A] 1989;11(Suppl 1):403-9.
214. Lee MR, Critchley JA, Gordon CJ, Makarananda K, Sriwatanakul K, Balali-Mood M, Boye GL. Ethnic differences in the renal sodium dopamine relationship. A possible explanation for regional variations in the prevalence of hypertension? Am J Hypertens 1990;3(6 Pt 2):100S-103S.
215. Iimura O, Shimamoto K. Salt and hypertension: water-sodium handling in essential hypertension. Ann N Y Acad Sci 1993;676:105-21.
216. Shikuma R, Yoshimura M, Ashizawa H, Kajita Y, Takahashi H, Takeda K, Ijichi H. Enhanced vascular reactivity to norepinephrine in salt-sensitive patients with hypertension. Jpn Heart J 1982;23(6):861-9.
217. Yoshimura M, Ikegaki I, Nishimura M, Takahashi H. Role of dopaminergic mechanisms in the kidney for the pathogenesis of hypertension. J Auton Pharmacol 1990;10(Suppl 1):s67-72.
218. Gill JR, Jr., Gullner G, Lake CR, Lakatua DJ, Lan G. Plasma and urinary catecholamines in salt-sensitive idiopathic hypertension. Hypertension 1988;11(4): 312-9.
219. Saito I, Takeshita E, Saruta T, Nagano S, Sekihara T. Urinary dopamine excretion in normotensive subjects with or without family history of hypertension. J Hypertens 1986;4(1):57-60.
220. Clark BA, Rosa RM, Epstein FH, Young JB, Landsberg L. Altered Dopaminergic Responses In Hypertension. Hypertension 1992;19(6):589-594.
221. Carey RM, Stote RM, Dubb JW, Townsend LH, Rose CE, Jr., Kaiser DL. Selective peripheral dopamine-1 receptor stimulation with fenoldopam in human essential hypertension. J Clin Invest 1984;74(6):2198-207.
222. Weber AB. Red-cell lithium-sodium countertransport and renal lithium clearance in hypertension. New England Journal of Medicine 1986;314:198-201.
223. O'Connell DP, Ragsdale NV, Boyd DG, Felder RA, Carey RM. Differential human renal tubular responses to dopamine type 1 receptor stimulation are determined by blood pressure status. Hypertension 1997;29(1 Pt 1):115-22.
224. Sanada H, Jose PA, Yu PY, Hazen-Martin D, Carey RM, Bruns D, Felder RA. Human hypertensive subjects have a renal proximal tubular defect in dopamine-1 receptor-adenylyl cyclase coupling. Journal of the American Society of Nephrology 1997;9(PROGRAM AND ABSTR. ISSUE):307A.
225. Lee MR. Dopamine, the kidney and essential hypertension. Clin. Exp. Hypertens., Part A Theory Pract 1989;1:149-158.
226. Worth DP, Harvey JN, Brown J, Lee MR. Patients with essential hypertension have an exaggerated natriuretic response to the dopamine pro-drug glutamyl-dopa. J Hypertens Suppl 1985;3 Suppl 3:S179-81.
227. Kikuchi K, Miyama A, Nakao T, Takigami Y, Kondo A, Mito T, Ura N, Tsuzuki M, Iimura O. Hemodynamic and natriuretic responses to intravenous infusion of dopamine in patients with essential hypertension. Jpn Circ J 1982;46(5):486-93.
228. Andrejak M, Hary L. Enhanced dopamine renal responsiveness in patients with hypertension. Clin Pharmacol Ther 1986;40(6):610-4.
229. Hirata Y, Fukui K, Hayakawa H, Suzuki E, Sugimoto T, Kimura K, Matsuoka H. Renal effects of atrial natriuretic peptide during dopamine infusion. Am J Hypertens 1990;3(11):866-9.
230. Kuchel O, Shigetomi S. Defective dopamine generation from dihydroxyphenylalanine in stable essential hypertensive patients. Hypertension 1992;19(6 Pt 2):634-8.
231. Nielsen CB, Pedersen EB. Abnormal distal tubular sodium reabsorption during dopamine infusion in patients with essential hypertension evaluated by the lithium clearance methods. Clin Nephrol 1997;47(5):304-9.